Abstrakt

Introduction: Bacteriophages (viruses of bacteria) are used in the treatment of antibiotic‑resistant infections. Moreover, they are an important component of the mucosal microbiota. The objective of this study was to investigate the effects of T4 and A5/80 bacteriophages on the expression of genes involved in antimicrobial immunity, including Toll‑like receptors. Material/Methods: The expression of genes was determined in the A549 cell line using RT2 Profiler PCR Array. Results: Purified T4 and A5/80 phage preparations significantly affected the expression of 7 and 10 out of 84 examined genes, respectively. Discussion: Our results are important for phage therapy of bacterial infections and provide novel insights into the role of phages from the mucosal microbiota. They may also lead to novel applications of phages as antiviral and immunomodulatory agents.

Przypisy

• 1. Adams A.B., Ford M.L., Larsen C.P.: Costimulationblockade in autoimmunity and transplantation: TheCD28 pathway. J. Immunol., 2016; 197: 2045‑2050
  Google Scholar
• 2. Adams M.H.: Bacteriophages, Interscience Publishers,Inc., New York 1959
  Google Scholar
• 3. Aggarwala V., Liang G., Bushman F.D.: Viral communitiesof the human gut: metagenomic analysis of compositionand dynamics. Mob. DNA, 2017; 8: 12
  Google Scholar
• 4. Aktaş O.N., Öztürk A.B., Erman B., Erus S., Tanju S.,Dilege Ş.: Role of natural killer cells in lung cancer. J.Cancer Res. Clin. Oncol., 2018; 144: 997‑1003
  Google Scholar
• 5. Barr J.J., Auro R., Furlan M., Whiteson K.L., Erb M.L.,Pogliano J., Stotland A., Wolkowicz R., Cutting A.S., DoranK.S., Salamon P., Youle M., Rohwer F.: Bacteriophageadhering to mucus provide a non‑host‑derived immunity.Proc. Natl. Acad. Sci. USA, 2013; 110: 10771‑10776
  Google Scholar
• 6. Boratyński J., Syper D., Weber‑Dąbrowska B.,Łusiak‑Szelachowska M., Poźniak G., Górski A.: Preparationof endotoxin‑free bacteriophages. Cell. Mol. Biol.Lett., 2004; 9: 253‑259
  Google Scholar
• 7. Cha K., Oh H.K., Jang J.Y., Jo Y., Kim W.K., Ha G.U., KoK.S., Myung H.: Characterization of two novel bacteriophagesinfecting multidrug‑resistant (MDR) Acinetobacterbaumannii and evaluation of their therapeuticefficacy in vivo. Front. Microbiol., 2018; 9: 696
  Google Scholar
• 8. Dalman M.R., Deeter A., Nimishakavi G., Duan Z.H.:Fold change and p‑value cutoffs significantly altermicroarray interpretations. BMC Bioinformatics, 2012; 13 (Suppl. 2): S11
  Google Scholar
• 9. Galanos C., Lüderitz O., Westphal O.: A new methodfor the extraction of R lipopolysaccharides. Eur. J. Biochem.,1969; 9: 245‑249
  Google Scholar
• 10. Gonzales C.M., Williams C.B., Calderon V.E., HuanteM.B., Moen S.T., Popov V.L., Baze W.B., Peterson J.W.,Endsley J.J.: Antibacterial role for natural killer cells inhost defense to Bacillus anthracis. Infect. Immun., 2012;80: 234‑242
  Google Scholar
• 11. Górski A., Dąbrowska K., Międzybrodzki R.,Weber‑Dąbrowska B., Łusiak‑Szelachowska M.,Jończyk‑Matysiak E., Borysowski J.: Phages and immunomodulation.Future Microbiol., 2017; 12: 905‑914
  Google Scholar
• 12. Górski A., Jończyk‑Matysiak E., Łusiak‑SzelachowskaM., Międzybrodzki R., Weber‑Dąbrowska B., BorysowskiJ.: The potential of phage therapy in sepsis. Front. Immunol.,2017; 8: 1783
  Google Scholar
• 13. Górski A., Jończyk‑Matysiak E., Łusiak‑Szelachowska M., Międzybrodzki R., Weber‑Dąbrowska B., BorysowskiJ.: Bacteriophages targeting intestinal epithelial cells: apotential novel form of immunotherapy. Cell. Mol. LifeSci., 2018; 75: 589‑595
  Google Scholar
• 14. Górski A., Jończyk‑Matysiak E., Łusiak‑SzelachowskaM., Międzybrodzki R., Weber‑Dąbrowska B., BorysowskiJ.: Phage therapy in allergic disorders? Exp. Biol. Med.,2018; 243; 534‑537
  Google Scholar
• 15. Górski A., Jończyk‑Matysiak E., Łusiak‑SzelachowskaM., Weber‑Dąbrowska B., Międzybrodzki R., BorysowskiJ.: Therapeutic potential of phages in autoimmune liverdiseases. Clin. Exp. Immunol., 2018; 192: 1‑6
  Google Scholar
• 16. Górski A., Jończyk‑Matysiak E., Międzybrodzki R.,Weber‑Dąbrowska B., Borysowski J.: “Phage transplantationin allotransplantation”: Possible treatment ingraft‑versus‑host disease? Front. Immunol., 2018; 9: 941
  Google Scholar
• 17. Górski A., Międzybrodzki R., Weber‑Dąbrowska B.,Fortuna W., Letkiewicz S., Rogóż P., Jończyk‑Matysiak E.,Dąbrowska K., Majewska J., Borysowski J.: Phage therapy:Combating infections with potential for evolving frommerely a treatment for complications to targeting diseases.Front. Microbiol., 2016; 7: 1515
  Google Scholar
• 18. Górski A., Weber‑Dąbrowska B.: The potential roleof endogenous bacteriophages in controlling invadingpathogens. Cell. Mol. Life Sci., 2005; 62: 511‑519
  Google Scholar
• 19. Greenhough J., Papadakis E.S., Cutress R.I.,Townsend P.A., Oreffo R.O., Tare R.S.: Regulation of osteoblastdevelopment by Bcl‑2‑associated athanogene‑1(BAG‑1). Sci. Rep., 2016; 6: 33504
  Google Scholar
• 20. Hess N.J., Felicelli C., Grage J., Tapping R.I.: TLR10suppresses the activation and differentiation of monocyteswith effects on DC‑mediated adaptive immuneresponses. J. Leukoc. Biol., 2017; 101: 1245‑1252
  Google Scholar
• 21. Kaszowska M., Niedziela T., Maciejewska A., LukasiewiczJ., Jachymek W., Lugowski C.: Core oligosaccharideof Escherichia coli B‑the structure required for bacteriophageT4 recognition. Carbohydr. Res., 2015; 413: 51‑54
  Google Scholar
• 22. Kuzmich N.N., Sivak K.V., Chubarev V.N., PorozovY.B., Savateeva‑Lyubimova T.N., Peri F.: TLR4 signalingpathway modulators as potential therapeutics in inflammationand sepsis. Vaccines, 2017; 5: E34
  Google Scholar
• 23. Levada K., Guldiken N., Zhang X., Vella G., Mo F.R.,James L.P., Haybaeck J., Kessler S.M., Kiemer A.K., Ott T.,Hartmann D., Hüser N., Ziol M., Trautwein C., Strnad P.:Hsp72 protects against liver injury via attenuation ofhepatocellular death, oxidative stress, and JNK signaling.J. Hepatol., 2018; 68: 996‑1005
  Google Scholar
• 24. Lu X., Nagata M., Yamasaki S.: Mincle: 20 years ofa versatile sensor of insults. Int. Immunol., 2018; 30:233‑239
  Google Scholar
• 25. Łobocka M., Hejnowicz M.S., Dąbrowski K., GozdekA., Kosakowski J., Witkowska M., Ulatowska M.I.,Weber‑Dabrowska B., Kwiatek M., Parasion S., GaworJ., Kosowska H., Głowacka A.: Genomics of staphylococcalTwort‑like phages – potential therapeutics of thepost‑antibiotic era. Adv. Virus Res., 2012; 83: 143‑216
  Google Scholar
• 26. Łusiak‑Szelachowska M., Żaczek M.,Weber‑Dąbrowska B., Międzybrodzki R., Kłak M., FortunaW., Letkiewicz S., Rogóż P., Szufnarowski K.,Jończyk‑Matysiak E., Owczarek B., Górski A.: Phage neutralizationby sera of patients receiving phage therapy.Viral Immunol., 2014; 27: 295‑304
  Google Scholar
• 27. Międzybrodzki R., Fortuna W., Weber‑Dąbrowska B.,Gorski A.: Bacterial viruses against viruses pathogenicfor man? Virus Res., 2005; 110: 1‑8
  Google Scholar
• 28. Międzybrodzki R., Fortuna W., Weber‑DąbrowskaB., Górski A.: A retrospective analysis of changes ininflammatory markers in patients treated with bacterialviruses. Clin. Exp. Med., 2009; 9: 303‑312
  Google Scholar
• 29. Murie C., Woody O., Lee A.Y., Nadon R.: Comparisonof small n statistical tests of differential expressionapplied to microarrays. BMC Bioinformatics, 2009; 10: 45
  Google Scholar
• 30. Przybylski M., Borysowski J., Jakubowska‑ZahorskaR., Weber‑Dąbrowska B., Górski A.: T4 bacteriophage‑mediatedinhibition of adsorption and replicationof human adenovirus in vitro. Future Microbiol., 2015;10: 453‑460
  Google Scholar
• 31. Schmidt S., Ullrich E., Bochennek K., ZimmermannS.Y., Lehrnbecher T.: Role of natural killer cells in antibacterialimmunity. Expert Rev. Hematol., 2016; 9:1119‑1127
  Google Scholar
• 32. Shepardson K.M., Schwarz B., Larson K., MortonR.V., Avera J., McCoy K., Caffrey A., Harmsen A., DouglasT., Rynda‑Apple A.: Induction of antiviral immuneresponse through recognition of the repeating subunitpattern of viral capsids is toll‑like receptor 2 dependent.MBio, 2017; 8: e01356‑17
  Google Scholar
• 33. Ślopek S., Durlakowa I., Weber‑Dąbrowska B.,Kucharewicz‑Krukowska A., Dąbrowski M., BisikiewiczR.: Results of bacteriophage treatment of suppurativebacterial infections. I. General evaluation of the results.Arch. Immunol. Ther. Exp., 1983; 31: 267‑291
  Google Scholar
• 34. Van Belleghem J.D., Clement F., Merabishvili M.,Lavigne R., Vaneechoutte M.: Pro‑ and anti‑inflammatoryresponses of peripheral blood mononuclear cellsinduced by Staphylococcus aureus and Pseudomonas aeruginosaphages. Sci. Rep., 2017; 7: 8004
  Google Scholar
• 35. Vijay K.: Toll‑like receptors in immunity and inflammatorydiseases: Past, present, and future. Int. Immunopharmacol.,2018; 59: 391‑412
  Google Scholar
• 36. Waggoner S.N., Reighard S.D., Gyurova I.E., CranertS.A., Mahl S.E., Karmele E.P., McNally J.P., Moran M.T.,Brooks T.R., Yaqoob F., Rydyznski C.E.: Roles of naturalkiller cells in antiviral immunity. Curr. Opin. Virol., 2016;16: 15‑23
  Google Scholar
• 37. Weber A.N., Bittner Z., Liu X., Dang T.M., RadsakM.P., Brunner C.: Bruton’s tyrosine kinase: An emergingkey player in innate immunity. Front. Immunol., 2017;8: 1454
  Google Scholar
• 38. Yap M.L., Rossmann M.G.: Structure and function ofbacteriophage T4. Future Microbiol., 2014; 9: 1319‑1327
  Google Scholar
• 39. Zhao L., Wang W.J., Zhang J.N., Zhang X.Y.: 5‑Fluorouraciland interleukin‑2 immunochemotherapyenhances immunogenicity of non‑small cell lung cancerA549 cells through upregulation of NKG2D ligands. AsianPac. J. Cancer Prev., 2014; 15: 4039‑4044
  Google Scholar
• 40. Zhu L., Shi T., Zhong C., Wang Y., Chang M., Liu X.:IL‑10 and IL‑10 receptor mutations in very early onsetinflammatory bowel disease. Gastroenterology Res.,2017; 10: 65‑69
  Google Scholar

Pełna treść artykułu